Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Supporting evidence

• Review decision

• Static list review decision – November 2017

• Static list review decision paper – November 2017 (PDF 156 KB)

  Published:

  17 November 2017

• Static list review consultation – September 2017

• Static list review proposal paper – September 2017 (PDF 309 KB)

  Published:

  11 September 2017

• Matrix for stakeholders – September 2017 (PDF 211 KB)

  Published:

  11 September 2017